InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China



BEIJING, March 01, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its next generation TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), for the treatment of pediatric patients (aged 2 to 12) with solid tumors harboring NTRK gene fusions. Priority review is one of the key policies introduced by the CDE to accelerate drug approval. Read More



Source link

  • Related Posts

    ¡Argentina está de regreso! La albiceleste remonta en un duelo cardíaco ante Egipto

    IE 11 no es compatible. Para una experiencia óptima, visite nuestro sitio en otro navegador. SIGUIENTE Enzo Fernández anota el 3-2 para dar la vuelta a Egipto 02:48 Messi se…

    Summer is the season of absenteeism: employers be aware

    Employers should establish clear expectations regarding availability, responsiveness, working hours, performance standards, travel outside the jurisdiction and occasions requiring in-person attendance. Employees cannot be disciplined for violating rules that were…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Rogers closes Vancouver radio stations News 1130 and Sportsnet 650

    Rogers closes Vancouver radio stations News 1130 and Sportsnet 650

    USPS to raise the price of a Forever stamp to 82 cents on Sunday. Here’s what to know.

    USPS to raise the price of a Forever stamp to 82 cents on Sunday. Here’s what to know.

    ¡Argentina está de regreso! La albiceleste remonta en un duelo cardíaco ante Egipto

    ¡Argentina está de regreso! La albiceleste remonta en un duelo cardíaco ante Egipto

    Saudi Arabia blocking payments to UAE accounts, businesses say

    Democrats’ narrow path to Senate majority gets rockier as Platner faces sexual assault allegation

    Democrats’ narrow path to Senate majority gets rockier as Platner faces sexual assault allegation

    Summer is the season of absenteeism: employers be aware